Vascular dementia, unspecified severity, with anxiety
Methodology & AI Transparency ⓘ
Vascular dementia, unspecified severity, with anxiety Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Alzheimer, Dementia & Memory Health practice, Vascular dementia, unspecified severity, with anxiety (ICD-10 F01.54) is stratified through targeted plasma/CSF biomarker in Vascular dementia, unspecified severity, with anxiety (F01.54: evaluation when indicated), pairing targeted symptom control with longitudinal TSH & Fasting in Vascular dementia, unspecified severity, with anxiety (F01.54: ApoB / HbA1c) surveillance.
- 2 Real-world patient consensus: Mapped to Alzheimer, Dementia & Memory Health under ICD-10-CM F01.54 for Vascular dementia, unspecified severity, with anxiety clinical workups.
- 3 Typical cash cost range: Differential triage of Vascular dementia, unspecified severity, with anxiety (F01.54) utilizes targeted plasma/CSF biomarker in Vascular dementia, unspecified severity, with anxiety (F01.54: evaluation when indicated).
- 4 Top reported side effects / signs: Objective lab/clinical target for Vascular dementia, unspecified severity, with anxiety: Homocysteine & Vitamin in Vascular dementia, unspecified severity, with anxiety (F01.54: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (F01.54)) and TSH & Fasting in Vascular dementia, unspecified severity, with anxiety (F01.54: ApoB / HbA1c).
Ask our AI Specialists anything about Vascular dementia, unspecified severity, with anxiety
What Is Vascular dementia, unspecified severity, with anxiety?
Within Alzheimer, Dementia & Memory Health practice, Vascular dementia, unspecified severity, with anxiety (ICD-10 F01.54) is stratified through targeted plasma/CSF biomarker in Vascular dementia, unspecified severity, with anxiety (F01.54: evaluation when indicated), pairing targeted symptom control with longitudinal TSH & Fasting in Vascular dementia, unspecified severity, with anxiety (F01.54: ApoB / HbA1c) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Vascular dementia, unspecified severity, with anxiety (ICD-10 F01.54) is driven by cortical synaptic attrition [Vascular dementia, unspecified severity, with anxiety F01.54]; specialists in Alzheimer, Dementia & Memory Health monitor TSH & Fasting in Vascular dementia, unspecified severity, with anxiety (F01.54: ApoB / HbA1c) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Vascular dementia, unspecified severity, with anxiety (F01.54): subtle personality shifts, in Vascular dementia, unspecified severity, with anxiety (F01.54: apathy, or evening)
- • Secondary Vascular dementia, unspecified severity, with anxiety clinical sign: slowed processing speed in Vascular dementia, unspecified severity, with anxiety (F01.54: compared with prior)
- • Symptom flares in Vascular dementia, unspecified severity, with anxiety correlating with Homocysteine & Vitamin in Vascular dementia, unspecified severity, with anxiety (F01.54: B12) deviation outside Homocysteine < 9 umol/L; B12 > 500 pg/mL (F01.54)
- • Functional memory & cognition impact requiring targeted plasma/CSF biomarker in Vascular dementia, unspecified severity, with anxiety (F01.54: evaluation when indicated) evaluation (F01.54)
Vascular dementia, unspecified severity, with anxiety Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F01.54 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Vascular dementia, unspecified severity, with anxiety (F01.54: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (F01.54) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Vascular dementia, unspecified severity, with anxiety (F01.54: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (F01.54) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Vascular dementia, unspecified severity, with anxiety (F01.54: Score) | >= 26 / 30 (F01.54) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vascular dementia, unspecified severity, with anxiety
Treatment selection for Vascular dementia, unspecified severity, with anxiety depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vascular dementia, unspecified severity, with anxiety)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Lancet (London, England) • 2017-06-03 • Meta-Analysis | N = 8,407 | 99/100 | PMID 28390695 ↗ |
| New Insights on Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and: What a 21,135-Participant Study Found GLP1RA therapy when compared to placebo reduced all-cause mortality in high heart and blood vessel risk patients with type 2 diabetes. Current diabetes reviews • 2018-01-15 • Meta-Analysis | N = 21,135 | 99/100 | PMID 28413990 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
| New Insights on Association between testosterone replacement therapy and heart and blood vessel: What a 11,502-Participant Study Found Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality. Progress in cardiovascular diseases • 2024-01-15 • Meta-Analysis | N = 11,502 | 99/100 | PMID 38589271 ↗ |
Vascular dementia, unspecified severity, with anxiety Patient Community & “People Like Me” Threads
Filter Vascular dementia, unspecified severity, with anxiety community threads and patient logs by age, biological sex, dosage, and treatment duration.